Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Hip Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Age ≥ 18 years~  * general anasthesia~ * Elective isolated unilateral HAS for any reason~ * No Prior hip surgery~ * Written informed consent as documented by signature (Appendix Informed Consent Form)~ * Competent German language skills~Exclusion Criteria:~* • Chronic pain patient, chronic lower back pain~  * Steroid or immunosuppressive drugs used within 6 months of surgery~ * Renal failure, hepatic failure~ * Relevant allergies~ * Pregnancy/ Breast feeding~ * Contraindications for Fortecortin treatment according to Swissmedic~ * Previous enrollment into the current study~ * Participation in another study with investigational drug within the 30 days preceding and during the present study~ * Known or suspected non-compliance, drug or alcohol abuse~ * Illness according to Warnings and Precautions of Dexamethasone and NaCl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dexamethasone group (Type: ACTIVE_COMPARATOR): The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
- Placebo/ Control group (Type: PLACEBO_COMPARATOR): The patients will not receive any additional drugs preoperatively. A 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.

Based on this trial design, predict the completion outcome and termination type (if applicable).